Stevia Corp., an international farm management company and healthcare company, has announced the filing of a second important provisional patent application with the United States Patent and Trademark Office for pain treatment using a combination of ibuprofen and cannabidiol (CBD).
The provisional patent application closely follows the company's previously announced first provisional patent application for pain management using acetaminophen and CBD. As in the previous application, this patent includes multiple claims including, but not limited to, combinations of cannabinoids including CBD and ibuprofen for the treatment of pain.
The provisional patent application, a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals, "was filed with the assistance of an intellectual property attorney with extensive experience in the healthcare industry," according to a prepared statement from Stevia Corp.
CBD is a cannabinoid present in most varieties of the cannabis sativa and cannabis indica plants. Unlike THC and some of the other molecules found in cannabis, CBD is non-psychoactive.
CBD is also extremely well tolerated at high doses with little or no side effects; it is essentially non-toxic. It catapulted to national prominence after being an important part of Dr. Sanjay Gupta's 2013 CNN documentary, "Weed."
Utah-based Dose of Nature last week launched a state-of-the-art CBD (cannabidiol) product line, applying proprietary technologies to create what it calls "the first nano CBD and water-soluble CBD products in the market."
CBD has been at the forefront of the news lately in its application to treat pediatric epilepsy, autism, cancer, pain, PTSD, brain injuries, anxiety, and various neurological conditions.
Most CBD pastes or oils being used today have a very strong taste and are slowly and poorly absorbed into the body. Dose of Nature says it addresses these issues using its proprietary Hydrosome™ and BioXTrax™ technologies, making water-soluble CBD taste better, more rapidly absorbed, and more bioavailable within minutes of ingestion.
"The Hydrosome™ technology represents a shift in how nutritional supplements, and even pharmaceuticals, can be delivered," said Dr. Rick Potts, president of Dose of Nature. "This integrative approach is far superior to liposomes in terms of unlocking the true potential of natural remedies, optimizing the speed and breadth of nutrient delivery throughout the body."
The new Dose of Nature product line will include:
• Sweet CBD™: this water-soluble form of concentrated CBD is readily absorbed in the stomach, and is created through a multiplex bonding process of highly-refined RedStrap CBD Oil to 100% vegetable glycerin without the need for preservatives, flavors, or emulsifying agents.
Florida's medical marijuana initiative lost momentum in 2014 after falling just short of the 60 percent needed to pass. But most Floridians believe that it's no longer a question of it, but when, medicinal cannabis comes to the Sunshine State.
The fact of the matter is that nearly 3.5 million Florida voters supported Amendment 2 -- medical marijuana -- in 2014. United for Care has already begun the process of collecting signatures to get medical marijuana back on the ballot for 2016, and pressure is mounting on the Florida Legislature to expand the already existing CBD-only "Charlotte's Web" law to include higher-THC strains as well.
That's why Sheridan Rafer, founder of the Institute of Medical Cannabis in Boca Raton, says "2015 should actually be a big year for medical marijuana and we will continue to provide education and training."
According to Rafer, last year, the Institute of Medical Cannabis, or IMC Florida for short, signed up more than 300 members and trained more than 100 individuals. The Institute offers four courses, primarily focusing on cultivation.
At IMC, students learn about medical marijuana and the medicinal cannabis industry while attending lectures and receiving practical training in "fully operational grow rooms." However, the Institute notes, "Until changes are initiated in the state and/or federal law, all hands-on training at IMC will be conducted with vegetables and herbs which are organically similar to cannabis."
CannaVest Corp., a manufacturer and distributor of hemp and cannabidiol (CBD) based products, announced on Thursday that "the results of independent testing have proved the safety and quality of its products."
In December, CannaVest Corp. commenced cooperative efforts with Project CBD to ensure the cannabis/hemp industry and the consuming public is provided with accurate and meaningful information concerning CannaVest Corp.'s CBD offerings. Project CBD is a non-profit educational service dedicated to promoting and publicizing research into the medical utility of cannabidiol (CBD).
CannaVest Corp. initiated its cooperative efforts with Project CBD in response to a special report on the hemp oil industry published by Project CBD titled "Hemp Oil Hustlers" on October 14, 2014 and revised on November 5, 2014.
Project CBD reported that a consumer product, which is labeled as containing hemp oil and which was produced by the company and then sold in 2013 to a distributor, tested positive for hexane and other solvent residues.
Following the publication of the Project CBD report, CannaVest agreed to work with Project CBD to independently test its products. Based on the results of this testing, Project CBD has concluded that CannaVest Corp.'s products are not contaminated with heavy metals or industrial solvent residues in amounts that pose health and safety issues for consumers, according to officially recognized safety standards.
CannaVest and Project CBD have released a joint statement.
By Steve Elliott
Brazil will soon study the possibility of legalizing the use of cannabidiol (CBD), a marijuana derivative, to treat people suffering from severe seizures.
The country's Health Surveillance Agency, ANVISA, announced that the "reclassification" of the cannabinoid CBD -- which is illegal in Brazil -- will be discussed starting next month, reports the Associated Press.
The statement came on Friday, one day after about 40 people protested in the capital city of Brasilia to demand the legalization of CBD.
Some Brazilians resort to an underground network of illegal cannabis farmers in Rio de Janeiro that extract the CBD and donate it. That network supplies Margaret de Brito with the oil she gives her five-year-old daughter Sofia, who was born with a genetic mutation that causes seizures.
"They won't even let you pay the shipping," Brito said of the clandestine growers' group.
Her daughter's seizures have decreased dramatically since starting the treatment more than a year ago, and she's been able to stop taking another medication that made her drowsy, Brito said.
The Federal Medical Council, which regulates the medical profession in Brazil, earlier this month authorized neurologists and psychiatrists to prescribe CBD to treat epileptic children and teenagers who don't respond to conventional pharmaceuticals. (You'd think a non-toxic alternative would be the first line of treatment, not the last resort!)
By Steve Elliott
South Carolina state Sen. Tom Davis (R-Beaufort), author of a bill which made it legal for parents to possess the marijuana derivative cannabidiol (CBD) oil to control their children's seizures, plans to introduce another bill on January 13, the first day of the upcoming legislative session, to allow low-THC marijuana to be grown in the state. But state law enforcement has already expressed opposition to the plan.
Davis said he first heard about CBD oil from a constituent whose granddaughter in Charleston was having 80 to 90 seizures an hour, reports Steve Jones at The State. Within two weeks of his constituent's granddaughter getting CBD oil, Davis said, the seizures were reduced by 80 percent.
After researching, Sen. Davis learned that CBD oil had helped people in other states, so he introduced a bill which passed and was signed into law by Gov. Nikki Haley last summer. The new law made legal the possession of CBD oil to treat children with uncontrollable epileptic seizures, as long as it was authorized by a physician.
The bill limits the amount of tetrahydrocannabinol (THC) that can be in the oil (THC is the main psychoactive ingredient in marijuana). It is limited by the bill to just 0.09 percent, far below what is needed to produce a high.
By Steve Elliott
Electronic cigarettes containing extracts of marijuana -- but no psychoactive THC -- are about to hit the market in France any day now. The e-cigs contain cannabinoids, including cannabidiol (CBD), which give relaxing and pain-killing effects, according to the manufacturer.
Three young French entrepreneurs are launching the product, which launches before the end of December, and they claim it will be entirely legal, reports The Local.
"KanaVape brings you many of the benefits of cannabinoids without the psychotic effect of THC," claims the website of the product, due to go on sale this month in France.
"Vape pens" which allow consumers to inhale cannabis or tobacco vapor are increasingly popular in the United States. But they've been rare in Europe until now.
"By using only hemp with 5 percent CBD (Cannabidiol) and no THC, KanaVape provides you with a unique cannabinoids excperience," the company claims. "Cannabidiol is a non-psychotic cannabinoid, it will not make you 'high' but will help you relax." (Note the not-very-subtle substitution of the word "psychotic" for the proper term, "psychoactive," perhaps to demonize THC and make it seem more threatening -- a favorite, albeit quite deceptive, marketing strategy for "CBD-only" purveyors.)
CBD-rich hemp, which is grown legally to make products such as oil, rope, cloth, paper, and fuel, will be used to make the vapor mix.
By Steve Elliott
The federal Food and Drug Administration has given the University of Alabama at Birmingham the go-ahead to study the use of cannabidiol, a marijuana derivative, to treat seizures.
The university on Wednesday received FDA letters authorizing two studies, one for children and one for adults, according to UAB spokesman Bob Shepard, reports Kim Chandler at the Associated Press.
Parents of children with severe seizure disorders convinced the Alabama Legislature last year to pass a bill authorizing UAB's Department of Neurology to perform a study of cannabidiol (CBD), a nonpsychoactive component of marijuana.
Shepard said the FDA had requested some changes in the studies; those will go before a university review board next month, he said.
"It's hard to put in words the feelings you have as a dad with a daughter that could benefit from this," said Dustin Chandler. The legislation had become known as "Carly's Law" after Chandler's three-year-old daughter, who started having seizures at just eight weeks old.
Carly was eventually diagnosed with the rare genetic disorder CDKL5. Chandler, a police officer in Pelham, frequently appeared before the Legislature to advocate for the bill.
By Steve Elliott
A portable analyzer instrument called the Cannalyzer-420™ is now avaialble; the product is designed to measure marijuana potency including THC, CBD, and more, according to the makers, Seattle-based LightWave Science, Inc.
Infrared technology is used in the Cannalyzer, according to the company, similar to that used by the U.S. Department of Agriculture on farm products for more than a decade.
The patent-pending instrument allows more growers, extractors, and dispensaries to quickly determine the quality their cannabis using infrared technology with repeatable accuracy within 1 percent, according to LightWave Science, Inc.
The idea is to save lots of time by not having to continuously send cannabis samples to expensive testing laboratories. "Use it when purchasing trim for your extracts or new product opportunities arriving at your back door," the company advises.
The Cannalyzer-420 measures marijuana flowers and leaves for the percentage of THC, CBD, and moisture, using non-contact, non-destructive infrared technology, according to the company. The Cannalyzer is a "grind and measure" unit which works by grinding the product into a sample dish, then placing it onto the measurement area to see instant results displayed onscreen.
The small, lightweight case is 6"x11"x14", with internal battery for 8 hours of operation in the field, according to the company. No internet connection is required.
Options are available to additionally measure extracts such as oils and dabs, according to LightWave Science, Inc.
By Steve Elliott
BreedIT Corp., through its Israeli subsidiary, BreedIT Ltd., on Tuesday announced that its joint venture, KanaboSeed Ltd., has submitted applications for the registration of two new cannabis strains to the Israeli Ministry of Agriculture & Rural Development Plant Breeders' Rights Council.
The new varieties of marijuana are the first to be developed by the KanaboSeed organization since the venture was formed in August of this year. Characterized by phenotypic and genotypic traits, the strains were cultivated to achieve CBD-to-THC ratios identified by the company's Scientific Advisory Board as likely to be effective in the management of particular medical conditions.
"We formed KanaboSeed to leverage the horticultural expertise of Seach Ltd., a licensed Israeli medical cannabis grower, with the technical and research capabilities of BreedIT Ltd., as well as our iBreedIT software platform," said Dr. Oded Sagee, CEO of BreedIT Ltd. ":Working together we are able develop and evaluate new strains relatively quickly, thereby reducing the timeline from research to market.
"These two registration applications are just the first for what we anticipate will be a line of new potential cannabis varieties that KanaboSeed is developing to address specific medical uses," Dr. Sagee said. "We intend to capitalize on the commercialization of new varieties, as allowed by the laws and regulations, in Israel and other countries where regulation permits the use of medical cannabis."
UsCBDpur, an importer of CBD extracted from industrial hemp and containing no THC, on Tuesday announced that they are now offering 100 gram to 1 kilo lots.
UsCBDpur says its cannabidiol is non-synthetic and represents a breakthrough in the clean extraction of CBD from thousand year old cultivars of Asian hemp (old strains bred for high fiber with little regard for any THC content).
"UsCBDpur contains no heavy metals, no THC and no residual cannabinoids/terpenes," states a prepared releasea from the company. It is simply PURE CBD, consistently testing at 99%+ pure!"
The company has what it calls "an affordable 100g entry level" beginning at $12,000. This means they are charging a stiff $120 a gram even at that volume. Rick Simpson Oil (RSO) and Full Extract Cannabis Oil (FECO) often sell for $25 to $40 a gram in the medical marijuana community -- at the single-gram level -- for comparison purposes.
"We decided to provide affordable entry levels for smaller manufacturers and formulation or consultation companies," said company director David Mouser. "If you do the math, it's a 7:1 ratio in costs.
"Everyone will enjoy cutting their CBD oil costs," Mouser said. "And think of the possibilities of pure powder formulations! That's huge, plus it is 100 percent CLEAN."
Expanding from its home market in Los Angeles, Nestdrop, which calls itself "the country's first completely in-App, on-demand medical marijuana delivery service," is now available for San Francisco patients on Android smartphones and tablets.
Medical marijuana patients will be required to upload a photo of valid ID and either a doctor's recommendation or medical marijuana identification card to Nestdrop's securely encrypted vault to receive approval before ordering. Unlike other online medical marijuana delivery services, Nestdrop says it is the first to provide an entirely in-app marketplace experience and orders will be fulfilled within an hour or less.
Nestdrop's medical marijuana service is currently available on Android throughout San Francisco as well as parts of Oakland and San Jose. More cities in the Bay Area will be added regularly.
"Expanding into San Francisco marks a milestone for us as we continue our mission of providing a safe method for medical marijuana patients to get the medicine they need in a convenient, discrete fashion," said Nestdrop co-founder Michael Pycher. "We are also excited to be the first medical marijuana delivery service in two major markets, with more on the way."
Plans Expansion of Line Of Hemp CBD Oils to Compete with Leading Pharmaceutical Products
Florida-based nutraceuticals company Zappy, Inc. has agreed to acquire Browns Botanicals and plans to release proprietary hemp CBD formulations for potential aid in various ailments including anxiety, insomnia, fatigue, nausea, pain and other ailments.
The formulations were developed using Hemp CBD Oil derived from industrial hemp, which it says is legal in all 50 states and 40 countries. Browns Botanicals is a nutraceutical leader specializing in the highest purity legal Hemp CBD-rich botanical products.
"We are honored to have Browns Botanicals as the backbone of the hemp-derived cannabinoids and terpenes science that we are bringing to customers," said Mike "Zappy" Zapolin, CEO of Zappy Inc. "Browns is well known in the industry for having the very best CBD products, and testimonials from customers with various illnesses, including epilepsy and several different auto-immune issues, are incredible."
Browns Botanicals recently won the first ever "Best Non-Edible Medically Infused Product" at the 2014 Cannabis Cup with an Industrial Hemp-derived CBD oil product, beating out the competition with their CBDemu, which is being used by Olympic athletes and sports teams.
Pan's Ink and Michigan Hemp Company on Tuesday announced they have entered into a strategic supply agreement through which Pan's Ink will provide tailored, natural terpene mixtures in bulk to Michigan Hemp Company for use in MHC's hemp CBD products. Pan's Ink will distribute its terpene mixtures to MHC under the Pan's Ink brand, TerpAid™.
Terpenes are an essential part of hemp and cannabis medicine, just as are the cannabinoids, including cannabidiol (CBD). These aromatic compounds work in concert to promote healing and well being through the "entourage effect."
Pan's Ink is known in the legal cannabis, smoking accessories, and aromatherapy industries for its line of terpene customization products. These products are used by customers to target the effects of their legal cannabis or other herbal smoking products in order to provide consistent symptom relief.
Pan's Ink also supplies balanced terpene profiles in bulk form to manufacturers. "We are thrilled to be working with hemp pioneers Joe Brown and the Michigan Hemp Company in this new venture," said Jack Turner, CEO and Founder of Pan's Ink.
"Terpenes are an integral part of cannabis medicine, and our 100 percent natural terpenes are the best in the industry," Turner said. "Teaming up with Michigan Hemp Company will gain Pan's Ink a valuable new relationship and will allow Michigan Hemp Company to augment its already cutting-edge products."
Researchers announce that clinical trials involving anti-convulsive form of marijuana is showing "promise" in children
As promising results from clinical trials are announced in the use of medicinal cannabis (medical marijuana) to treat intractable epilepsy, those lawfully cultivating the plant in California are being raided by local law enforcement. Two gardens destroyed by police in the past two months in Mendocino County and Modesto contained a rare strain of medical marijuana rich in Cannabidiol (or CBD) used by children many of whom do not respond to other drug treatments.
On August 5, unidentified men in camouflage dropped from an unmarked helicopter onto the 120-acre property of Potter Valley resident and cancer survivor Susan Schindler, cutting down her lawfully cultivated medical marijuana plants. In addition to growing for herself, Schindler was cultivating rare strains of medical marijuana rich in CBD, a non-psychotropic constituent of the plant, which were being used orally by children with epilepsy.
Schindler was also cultivating plants rich in THCV, another active constituent (or cannabinoid) that was producing positive results for a patient with Parkinson's disease.